Epidemiology of Rotavirus Infection in North India Community
NCT ID: NCT01508533
Last Updated: 2012-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
200 participants
OBSERVATIONAL
2009-07-31
2010-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase III Clinical Trial to Evaluate the Protective Efficacy of Three Doses of Oral Rotavirus Vaccine (ORV) 116E
NCT01305109
Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)
NCT00496054
Phase I Clinical Trial of Inactivated Rotavirus Vaccine in a Population Aged 6 Weeks-49 Years Old
NCT06350058
The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E
NCT05958771
Safety and Immunogenicity Study of Live Attenuated Indian Rotavirus Vaccine Candidate Strains 116E and I321 in Infants
NCT00280111
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Weekly contact were made by field workers for both the cohorts. At each contact cases of gastroenteritis were identified. All infants with gastroenteritis were assessed by a field worker/clinical coordinator. The child was assessed for presence of dehydration, danger signs. The field worker/clinical coordinator ensured that at least one diarrheal stool specimen was collected for each episode of gastroenteritis. Infants were treated at the study clinic or escorted to one of the identified hospitals, if required.
Caregivers of the enrolled infants were explained the signs and symptoms of suspected intussusception, dehydration and danger signs that require hospital referral and were given the option to seek care from the study clinic or from one of the identified hospitals in the vicinity.
Stool specimens were collected in all diarrheal episodes. In a subset of 30 children who were identified early in a diarrheal episode and who shed rotavirus, multiple stool specimens were collected in order to assess duration of shedding of rotavirus during a natural infection.
The study was also designed to collect information on data essential for planning and implementation of phase III trials pertaining to trial logistics, data collection tools and validity of questions including those in the Vesikari score.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1
Cohort 1: Infants enrolled at ≤1 week and followed up weekly till one year of age.
No interventions assigned to this group
Cohort 2
Cohort 2: Infants enrolled at 12 months and followed up weekly till they are aged 24 months.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Healthy infant aged ≤ 1 week - cohort I, children aged 12 months (+14 days)-Cohort 2
* Absence of any illness requiring hospitalization
* No confirmed plans to move in the next 12 months
Exclusion Criteria
* Any signs or symptoms of active sepsis, pneumonia, meningitis or any other disease requiring hospitalization
* Known case of immunodeficiency disease, known HIV positive
* Known case of chronic gastrointestinal disease
1 Day
24 Months
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Immunology, New Delhi
UNKNOWN
Ministry of Science and Technology, India
OTHER_GOV
Society for Applied Studies
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
NBhandari
Joint Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Nita Bhandari, PhD
Role: PRINCIPAL_INVESTIGATOR
Society for Applied Studies
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Society for Applied Studies
New Delhi, National Capital Territory of Delhi, India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SAS/BBIL/07/2008
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.